For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Zevra Therapeutics Inc’s stock clocked out at $7.94, up 0.25% from its previous closing price of $7.92. In other words, the price has increased by $0.25 from its previous closing price. On the day, 0.61 million shares were traded. ZVRA stock price reached its highest trading level at $8.2899 during the session, while it also had its lowest trading level at $7.62.
Ratios:
To gain a deeper understanding of ZVRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 2.53. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.51.
On October 07, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.
Maxim Group reiterated its Buy rating for the stock on September 24, 2024, while the target price for the stock was revised from $18 to $25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 13 ’25 when Sangiovanni Timothy J. sold 3,000 shares for $7.86 per share. The transaction valued at 23,588 led to the insider holds 16,341 shares of the business.
Schafer Joshua sold 10,500 shares of ZVRA for $82,527 on Feb 13 ’25. The CCO & EVP, Bus. Development now owns 29,486 shares after completing the transaction at $7.86 per share. On Feb 13 ’25, another insider, Clifton R. LaDuane, who serves as the CFO & Treasurer of the company, sold 11,000 shares for $7.86 each. As a result, the insider received 86,471 and left with 51,361 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 426145376 and an Enterprise Value of 416945440. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.95 while its Price-to-Book (P/B) ratio in mrq is 10.74. Its current Enterprise Value per Revenue stands at 17.658 whereas that against EBITDA is -5.168.
Stock Price History:
The Beta on a monthly basis for ZVRA is 1.91, which has changed by 0.32333338 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, ZVRA has reached a high of $9.76, while it has fallen to a 52-week low of $4.20. The 50-Day Moving Average of the stock is -0.06%, while the 200-Day Moving Average is calculated to be 7.94%.
Shares Statistics:
It appears that ZVRA traded 447.02K shares on average per day over the past three months and 540200 shares per day over the past ten days. A total of 53.67M shares are outstanding, with a floating share count of 52.81M. Insiders hold about 1.05% of the company’s shares, while institutions hold 63.75% stake in the company. Shares short for ZVRA as of 1740700800 were 5612280 with a Short Ratio of 12.55, compared to 1738281600 on 5522234. Therefore, it implies a Short% of Shares Outstanding of 5612280 and a Short% of Float of 10.5500005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
